P1, You've got me so wrong. I've never bashed Myriad. Once in a while I may mention a shortcoming or two but I've never bashed them. I wouldn't be here if I wasn't a bull.
In fact, I've always felt that I've been very complimentary towards you too. I've always been polite when I point out your infallible track record when it comes to predicting the future price of Myriad.
When you look at the pharma disaster du jour, PFE, specifically but also in the context of the illness of the industry, doesn't it become more likely that BP will shortly become more aggressive in attempting to gobble up promising bios?
In short, BP looks worth avoiding, and the biotechs look too cheap here
Big pharma is in the unfortunate position of being everyone's whipping boy. PFE and MRK have been beat around the head and shoulders enough that they have to show their contrition by reporting lousy numbers and laying a few folks off. Is it real or just a grand act? Either way, it's working, when's the last time you heard about Canadian drugs or congressional hearings?
I suppose you can remain nervous about PFE until the Lipitor cloud is gone but I'd have to say with a forward PE of 11 it's looking pretty cheap even if they loose Lipitor(unlikely).
I'm not sure that buying MYGN or any other bio would fit their current posture as NYSE martyr so I wouldn't hold my breath on that one.